Table 1:
Baseline characteristics of ISCHEMIA-CKD population based on survival
| Characteristic | Alive (N=585) |
Deaths | ||
|---|---|---|---|---|
| CV Death (N=94) |
Non-CV Death (N=59) |
Undetermined Death (N=39) |
||
| Demographics | ||||
| Median age (25th, 75th percentiles), years | 62 (54, 69) | 66 (57, 71) * | 67 (59, 74) ‡ | 65 (57, 70) |
| Male Sex, n/N (%) | 395/585 (67.5) | 70/94 (74.5) | 42/59 (71.2) | 28/39 (71.8) |
| Race, n/N (%) | ||||
| White | 360/562 (64.1) | 59/90 (65.6) | 42/57 (73.7) | 20/38 (52.6) |
| Black or African American | 45/562 (8.0) | 8/90 (8.9) | 3/57 (5.3) | 7/38 (18.4) |
| Asian | 149/562 (26.5) | 21/90 (23.3) | 10/57 (17.5) | 11/38 (28.9) |
| Other | 8/562 (1.4) | 2/90 (2.2) | 2/57 (3.5) | 0/38 (0.0) |
| Ethnicity, n/N (%) | ||||
| Hispanic or Latino | 74/552 (13.4) | 14/91 (15.4) | 10/54 (18.5) | 0/38 (0.0) |
| Not Hispanic or Latino | 478/552 (86.6) | 77/91 (84.6) | 44/54 (81.5) | 38/38 (100.0) |
| Region, n/N (%) | ||||
| Asia | 223/585 (38.1) | 28/94 (29.8) | 15/59 (25.4) | 21/39 (53.8) |
| Europe | 171/585 (29.2) | 36/94 (38.3) | 25/59 (42.4) | 7/39 (17.9) |
| Latin America | 34/585 (5.8) | 8/94 (8.5) | 7/59 (11.9) | 0/39 (0.0) |
| North America | 144/585 (24.6) | 18/94 (19.1) | 10/59 (16.9) | 11/39 (28.2) |
| Other | 13/585 (2.2) | 4/94 (4.3) | 2/59 (3.4) | 0/39 (0.0) |
| Clinical History | ||||
| Hypertension, n/N (%) | 536/582 (92.1) | 88/94 (93.6) | 53/58 (91.4) | 34/39 (87.2) |
| Diabetes, n/N (%) | 311/585 (53.2) | 67/94 (71.3)† | 34/59 (57.6) | 32/39 (82.1)† |
| Prior myocardial infarction, n/N (%) | 82/584 (14.0) | 26/94 (27.7)† | 16/59 (27.1)* | 9/39 (23.1) |
| Never smoked n/N (%) | 284/585 (48.5) | 39/94 (41.5) | 27/59 (45.8) | 21/39 (53.8) |
| Prior PCI, n/N (%) | 96/585 (16.4) | 27/94 (28.7)† | 14/59 (23.7) | 9/39 (23.1) |
| Prior CABG, n/N (%) | 20/585 (3.4) | 7/94 (7.4)* | 1/59 (1.7) | 0/39 (0.0) |
| Malignancy in the last 5 years, n/N (%) | 25/584 (4.3) | 4/94 (4.3) | 3/59 (5.1) | 1/39 (2.6) |
| Atrial fibrillation/atrial flutter, n/N (%) | 47/584 (8.0) | 12/94 (12.8) | 7/59 (11.9) | 3/39 (7.7) |
| On dialysis at baseline, n/N (%) | 305/585 (52.1) | 50/94 (53.2) | 36/59 (61.0) | 24/39 (61.5) |
| Non-Cardiac Vascular History | ||||
| Prior stroke, n/N (%) | 44/585 (7.5) | 13/94 (13.8) | 7/59 (11.9) | 4/39 (10.3) |
| Prior PVD, n/N (%) | 26/585 (4.4) | 12/94 (12.8)* | 6/59 (10.2) | 4/39 (10.3) |
| Ischemia Severity | ||||
| Severity, n/N (%) | ||||
| Severe | 98/462 (21.2) | 28/79 (35.4) | 15/51 (29.4) | 9/34 (26.5) |
| Moderate | 364/462 (78.8) | 51/79 (64.6) | 36/51 (70.6) | 25/34 (73.5) |
| Angina and Heart Failure History | ||||
| Prior heart failure (derived), n/N (%) | 136/585 (23.2) | 38/94 (40.4) ‡ | 14/59 (23.7) | 9/39 (23.1) |
| Median ejection fraction (25th, 75th) | 59 (50, 64) | 54 (45, 60) ‡ | 60 (49, 64) | 55 (46, 60) |
| N | 461 | 77 | 50 | 31 |
| Ejection fraction <50%, n/N (%) | 85/461 (18.4) | 28/77 (36.4) ‡ | 13/50 (26.0) | 9/31 (29.0) |
| Lab Values | ||||
| Median LDL-C (25th, 75th percentiles) mg/dL | 83.0 (62.0, 112.5) | 81.0 (58.0, 111.0) | 78.5 (50.0, 110.0) | 90.5 (53.5, 112.5) |
| LDL-C ≤70 mg/dL, n/N (%) | 193/544 (35.5) | 36/91 (39.6) | 24/56 (42.9) | 14/36 (38.9) |
| Median eGFR (25th, 75th percentiles) mL/min | 23 (17, 27) | 19 (16, 25) | 23 (18, 25) | 24 (15, 27) |
| Medications, n/N (%) | ||||
| Statins | 465/584 (79.6) | 80/94 (85.1) | 48/59 (81.4) | 36/39 (92.3) |
| Aspirin | 414/584 (70.9) | 79/94 (84.0)* | 49/59 (83.1) | 32/39 (82.1) |
| DAPT | 105/584 (18.0) | 23/94 (24.5) | 16/59 (27.1) | 10/39 (25.6) |
| Oral Anticoagulant | 59/573 (10.3) | 11/92 (12.0) | 6/59 (10.2) | 3/39 (7.7) |
| Beta Blocker | 433/584 (74.1) | 76/94 (80.9) | 43/59 (72.9) | 29/39 (74.4) |
| ACE Inhibitor or ARB | 273/584 (46.7) | 52/94 (55.3) | 26/59 (44.1) | 19/39 (48.7) |
| Calcium Channel Blocker | 333/584 (57.0) | 46/94 (48.9) | 31/59 (52.5) | 22/39 (56.4) |
| Long-acting Nitrate | 120/584 (20.5) | 27/94 (28.7)* | 8/59 (13.6) | 10/39 (25.6) |
CABG = coronary artery bypass grafting; CV = cardiovascular; DAPT = dual anti-platelet therapy; eGFR = estimate glomerular filtration rate; LDL-C = low density lipoprotein cholesterol; PCI = percutaneous coronary intervention; PVD = peripheral vascular disease.
*
Comparisons made with alive group, p < 0.05.
†
Comparisons made with alive group, p < 0.01.
‡
Comparisons made with alive group, p < 0.001.